The role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (DOACs)

Date: 23/11/2015
Location: European Medicines Agency, London, UK
This EMA workshop will bring together experts and stakeholders to discuss the utility of pharmacokinetic (PK) and pharmacodynamic (PD) measurements in the clinical use of the new direct oral anticoagulants (DOACs) and whether those could enhance the benefit-risk profile of these medicines by further reducing the risk of major bleedings while maintaining or improving the protection against thromboembolic events. The objectives of the workshop are to improve the understanding of the clinical use of DOACs, issues in relation to PK and PD measurements as well as priorities in future research.

Documents

Multimedia

How useful was this page?

Add your rating